Lilian Downie
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Lilian Downie has a total of 161 co-authors. Here are the top co-authors by number of shared publications:
- Zornitza Stark
Murdoch Children’s Research Institute, Melbourne, Australia
4 shared publications Clara Gaff
The University of Melbourne, Melbourne, VIC, Australia
3 shared publicationsErin Tutty
University of Melbourne, Melbourne, Australia
3 shared publicationsSebastian Lunke
Victorian Clinical Genetics Services Parkville Australia
3 shared publications- Sebastian Lunke
Murdoch Children's Research Institute
3 shared publications Alison D. Archibald
University of Melbourne, Melbourne, Australia
2 shared publications
Latest Publications
- Open Access
- 2 November 2026
- Published by Elsevier in Genetics in Medicine Open
Investigator perspectives on gene selection for public health genomic newborn screening
- 2 November 2026
- Published by Elsevier in Genetics in Medicine Open
Open AccessInvestigator perspectives on gene selection for public health genomic newborn screening
- 26 October 2026
- Published by Elsevier in Genetics in Medicine
Selection of Genetic Conditions for Multi-State Genomic Newborn Screening in BRIDGES-NBS
- 26 October 2026
- Published by Elsevier in Genetics in Medicine
Selection of Genetic Conditions for Multi-State Genomic Newborn Screening in BRIDGES-NBS
- Open Access
- 16 September 2026
- Published by Springer Nature in European Journal of Human Genetics
- p. 1-16
Global recommendations for the use of diagnostic genomic sequencing in the prenatal setting on behalf of the ESHG and ISPD
- 16 September 2026
- Published by Springer Nature in European Journal of Human Genetics
- p. 1-16
Open AccessGlobal recommendations for the use of diagnostic genomic sequencing in the prenatal setting on behalf of the ESHG and ISPD
- Open Access
- 15 September 2026
- Published by Wiley in Prenatal Diagnosis
- Vol. 46 (11) , 1683-1702
Global Recommendations for the Use of Diagnostic Genomic Sequencing in the Prenatal Setting on Behalf of the ESHG and ISPD
- 15 September 2026
- Published by Wiley in Prenatal Diagnosis
- Vol. 46 (11) , 1683-1702
Open AccessGlobal Recommendations for the Use of Diagnostic Genomic Sequencing in the Prenatal Setting on Behalf of the ESHG and ISPD
- Open Access
- 23 July 2026
- Published by Springer Nature in European Journal of Human Genetics
- p. 1-8
Scaling up genomic newborn screening: implementation lessons from the BabyScreen+ study
Interest in the potential of population-based genomic sequencing is growing. However, integrating a large-scale screening program into an already complex healthcare system is challenging. The implementation of gNBS needs a thorough understanding of the process. The purpose of this study is to investigate how gNBS can be integrated into the Australian health system and delivered at scale. Embedded within the BabyScreen+ study, we utilised a research design informed by process mapping and phenomenology. Fifty-one semi-structured interviews with parents ( n = 33), healthcare providers ( n = 15), and BabyScreen+ study team members ( n = 8) were conducted. Additionally, we analysed the operational team meeting minutes. A baseline process map, developed in consultation with team members, consisted of six stages: 1. Raising awareness of the screening program; 2. Offer; 3. Participant enrolment and consent; 4. Sample collection; 5. Testing; and 6. Result disclosure and management. We recorded changes made over the study period to inform the post-implementation process map. Most changes occurred at stages: 1. Raising awareness, 4. Sample collection and 5. Testing. Lastly, a process map to inform the scale up of screening, was developed. Four key aspects of the gNBS process needing modification are: (1) growing awareness of screening amongst the public and HCPs; (2) building flexibility and accessibility into the consent process; (3) developing automation capabilities and infrastructure for large-scale sequencing and analysis, and (4) dedicated referral processes for infants who receive high-chance results. These findings demonstrate key system-level considerations and provide a foundation for implementing genomic newborn screening at scale within existing healthcare systems.
- 23 July 2026
- Published by Springer Nature in European Journal of Human Genetics
- p. 1-8
Open AccessScaling up genomic newborn screening: implementation lessons from the BabyScreen+ study
Interest in the potential of population-based genomic sequencing is growing. However, integrating a large-scale screening program into an already complex healthcare system is challenging. The implementation of gNBS needs a thorough understanding of the process. The purpose of this study is to investigate how gNBS can be integrated into the Australian health system and delivered at scale. Embedded within the BabyScreen+ study, we utilised a research design informed by process mapping and phenomenology. Fifty-one semi-structured interviews with parents ( n = 33), healthcare providers ( n = 15), and BabyScreen+ study team members ( n = 8) were conducted. Additionally, we analysed the operational team meeting minutes. A baseline process map, developed in consultation with team members, consisted of six stages: 1. Raising awareness of the screening program; 2. Offer; 3. Participant enrolment and consent; 4. Sample collection; 5. Testing; and 6. Result disclosure and management. We recorded changes made over the study period to inform the post-implementation process map. Most changes occurred at stages: 1. Raising awareness, 4. Sample collection and 5. Testing. Lastly, a process map to inform the scale up of screening, was developed. Four key aspects of the gNBS process needing modification are: (1) growing awareness of screening amongst the public and HCPs; (2) building flexibility and accessibility into the consent process; (3) developing automation capabilities and infrastructure for large-scale sequencing and analysis, and (4) dedicated referral processes for infants who receive high-chance results. These findings demonstrate key system-level considerations and provide a foundation for implementing genomic newborn screening at scale within existing healthcare systems.
- Open Access
- 27 June 2026
- Published by Springer Nature in European Journal of Human Genetics
Australian parents’ perspectives on extended genomic screening: what information to return and when?
Genomic newborn screening (gNBS) has the potential to generate information that remains relevant across the lifespan, yet little is known about how families who have directly experienced gNBS, understand its long-term role and value. This study analysed the results of eight focus groups with 32 parents whose children had received findings from gNBS (through the BabyScreen+ study, a population-based Australian gNBS pilot programme), to explore how they conceptualise the use of genomic information beyond infancy (which we refer to as extended genomic sequencing, or eGS). Parents described a complex interplay of factors including treatability, severity, certainty, and personal capacity to manage information that shaped their desire to receive results. Using the Health Belief Model as a lens, we show how parental reflections mapped to constructs such as perceived benefits, barriers, severity, susceptibility, self-efficacy, and cues to action. However, parents’ reasoning was dynamic rather than static, illustrating how shifts in clinical options or family circumstances influence decision making over time. Overall, our findings demonstrate that families view gNBS data as a potential lifetime resource and support the need for flexible consent pathways, ongoing counselling, and governance frameworks that anticipate both the benefits and burdens of genomic information. This work offers timely insights to inform ethical implementation of eGS in Australia and contributes to international discussions about integrating genomic sequencing into population-level screening.
- 27 June 2026
- Published by Springer Nature in European Journal of Human Genetics
Open AccessAustralian parents’ perspectives on extended genomic screening: what information to return and when?
Genomic newborn screening (gNBS) has the potential to generate information that remains relevant across the lifespan, yet little is known about how families who have directly experienced gNBS, understand its long-term role and value. This study analysed the results of eight focus groups with 32 parents whose children had received findings from gNBS (through the BabyScreen+ study, a population-based Australian gNBS pilot programme), to explore how they conceptualise the use of genomic information beyond infancy (which we refer to as extended genomic sequencing, or eGS). Parents described a complex interplay of factors including treatability, severity, certainty, and personal capacity to manage information that shaped their desire to receive results. Using the Health Belief Model as a lens, we show how parental reflections mapped to constructs such as perceived benefits, barriers, severity, susceptibility, self-efficacy, and cues to action. However, parents’ reasoning was dynamic rather than static, illustrating how shifts in clinical options or family circumstances influence decision making over time. Overall, our findings demonstrate that families view gNBS data as a potential lifetime resource and support the need for flexible consent pathways, ongoing counselling, and governance frameworks that anticipate both the benefits and burdens of genomic information. This work offers timely insights to inform ethical implementation of eGS in Australia and contributes to international discussions about integrating genomic sequencing into population-level screening.
- Open Access
- 26 June 2026
- Published by Springer Nature in European Journal of Human Genetics
- p. 1-9
How parents decide whether to have genomic newborn screening: experiences from BabyScreen+
Education and consent processes for genomic newborn screening (gNBS) must be informed by evidence about parental decision-making. BabyScreen+ piloted gNBS for 1000 newborns in Victoria, Australia. Prospective parents consented online with genetic counselling available on request. We aimed to explore how BabyScreen+ participants ( n = 1139) made decisions about gNBS using a convergent parallel mixed methods design. Demographic ( n = 1080), survey ( n = 1010), and interview ( n = 24) data were analysed using descriptive statistics, logistic regression, and deductive content analysis mapped to the Health Belief Model (domains indicated in italics) . Most participants perceived low susceptibility of having a child with a genetic condition and found it difficult to conceptualise severity . Participants were motivated to consider gNBS due to benefits such as information about their child’s health, reassurance, and research contributions. Some perceived barriers included inequitable access to gNBS information, difficulty navigating high chance results, and potential data misuse. Most participants (987/1139, 87%) proceeded with gNBS because they believed barriers were outweighed by benefits or were manageable due to high self-efficacy . Remaining participants (152/1139, 13%) did not proceed with gNBS because benefits were unclear, or due to low self-efficacy . Experiences were modified by sociodemographic factors and the BabyScreen+ model of care. This research provides timely evidence about parental gNBS decision-making. It supports acceptability and feasibility of the BabyScreen+ model of care. Moving forward, education and consent processes must be equitable, tailored to individual context, and designed to foster self-efficacy. Such considerations will support decision-making and reduce psychological impacts for parents considering gNBS in the future.
- 26 June 2026
- Published by Springer Nature in European Journal of Human Genetics
- p. 1-9
Open AccessHow parents decide whether to have genomic newborn screening: experiences from BabyScreen+
Education and consent processes for genomic newborn screening (gNBS) must be informed by evidence about parental decision-making. BabyScreen+ piloted gNBS for 1000 newborns in Victoria, Australia. Prospective parents consented online with genetic counselling available on request. We aimed to explore how BabyScreen+ participants ( n = 1139) made decisions about gNBS using a convergent parallel mixed methods design. Demographic ( n = 1080), survey ( n = 1010), and interview ( n = 24) data were analysed using descriptive statistics, logistic regression, and deductive content analysis mapped to the Health Belief Model (domains indicated in italics) . Most participants perceived low susceptibility of having a child with a genetic condition and found it difficult to conceptualise severity . Participants were motivated to consider gNBS due to benefits such as information about their child’s health, reassurance, and research contributions. Some perceived barriers included inequitable access to gNBS information, difficulty navigating high chance results, and potential data misuse. Most participants (987/1139, 87%) proceeded with gNBS because they believed barriers were outweighed by benefits or were manageable due to high self-efficacy . Remaining participants (152/1139, 13%) did not proceed with gNBS because benefits were unclear, or due to low self-efficacy . Experiences were modified by sociodemographic factors and the BabyScreen+ model of care. This research provides timely evidence about parental gNBS decision-making. It supports acceptability and feasibility of the BabyScreen+ model of care. Moving forward, education and consent processes must be equitable, tailored to individual context, and designed to foster self-efficacy. Such considerations will support decision-making and reduce psychological impacts for parents considering gNBS in the future.
- 3 November 2025
- Published by Wiley in Prenatal Diagnosis
- Vol. 45 (13) , 1795-1798
A de novo WBP11 Pathogenic Variant in a Fetus With Cystic Brain Malformation and Growth Restriction
We report the first prenatal diagnosis of a de novo WBP11 variant in a fetus with growth restriction and structural brain anomalies. The case highlights the challenges of counselling with a new and evolving gene‐disease association.
- 3 November 2025
- Published by Wiley in Prenatal Diagnosis
- Vol. 45 (13) , 1795-1798
A de novo WBP11 Pathogenic Variant in a Fetus With Cystic Brain Malformation and Growth Restriction
We report the first prenatal diagnosis of a de novo WBP11 variant in a fetus with growth restriction and structural brain anomalies. The case highlights the challenges of counselling with a new and evolving gene‐disease association.
- Open Access
- 26 March 2025
- Published by Wiley in Australian and New Zealand Journal of Obstetrics and Gynaecology
- Vol. 65 (6) , 745-751
Insights and Experiences From the ‘Gatekeepers’: A Qualitative Study Exploring Clinician Perspectives on Providing Publicly Funded Prenatal Exome Sequencing
Background: Genomics has improved etiological diagnosis for foetal structural anomalies. It is being increasingly utilised in prenatal investigation both in Australia and internationally. To date, literature reporting diagnostic yield according to indication has been available. There is limited literature around the challenges of implementation and other aspects of utility. Aims: We aimed to explore the experiences and perspectives of clinicians involved with the delivery of a state‐wide public prenatal exome sequencing (pES) service in Australia. Materials and Methods: This qualitative study was developed using a pragmatism framework. A multidisciplinary cohort of clinicians across all tertiary foetal medicine units in Victoria was interviewed. Inductive content analysis was used to understand the experiences, impact, and utility of pES. Results: Eight clinician interviews were analysed. The impact of pES on clinicians included: increased pressure, higher emotional toll, and balancing the benefits with resource limitations. PES was most useful when it provided prognostic information. The clinicians felt that pES had the most utility for patients when the result informed their decision about whether or not to continue a pregnancy. Clinicians acknowledged their ‘gatekeeper’ role and valued a collaborative, multidisciplinary approach. The main perceived harm for patients was the anxiety associated with waiting times for results. Conclusions: This study provides insights into the delivery of a publicly funded pES program. Our findings highlight the importance of the multidisciplinary team in the successful implementation of genomic technologies in reproductive health.
- 26 March 2025
- Published by Wiley in Australian and New Zealand Journal of Obstetrics and Gynaecology
- Vol. 65 (6) , 745-751
Open AccessInsights and Experiences From the ‘Gatekeepers’: A Qualitative Study Exploring Clinician Perspectives on Providing Publicly Funded Prenatal Exome Sequencing
Background: Genomics has improved etiological diagnosis for foetal structural anomalies. It is being increasingly utilised in prenatal investigation both in Australia and internationally. To date, literature reporting diagnostic yield according to indication has been available. There is limited literature around the challenges of implementation and other aspects of utility. Aims: We aimed to explore the experiences and perspectives of clinicians involved with the delivery of a state‐wide public prenatal exome sequencing (pES) service in Australia. Materials and Methods: This qualitative study was developed using a pragmatism framework. A multidisciplinary cohort of clinicians across all tertiary foetal medicine units in Victoria was interviewed. Inductive content analysis was used to understand the experiences, impact, and utility of pES. Results: Eight clinician interviews were analysed. The impact of pES on clinicians included: increased pressure, higher emotional toll, and balancing the benefits with resource limitations. PES was most useful when it provided prognostic information. The clinicians felt that pES had the most utility for patients when the result informed their decision about whether or not to continue a pregnancy. Clinicians acknowledged their ‘gatekeeper’ role and valued a collaborative, multidisciplinary approach. The main perceived harm for patients was the anxiety associated with waiting times for results. Conclusions: This study provides insights into the delivery of a publicly funded pES program. Our findings highlight the importance of the multidisciplinary team in the successful implementation of genomic technologies in reproductive health.
- Open Access
- 8 March 2025
- Published by Wiley in Prenatal Diagnosis
- Vol. 45 (10) , 1277-1280
The Intersection Between Genetic Reproductive Carrier Screening and Genomic Newborn Screening: Implications for Clinical Practice
- 8 March 2025
- Published by Wiley in Prenatal Diagnosis
- Vol. 45 (10) , 1277-1280
Open AccessThe Intersection Between Genetic Reproductive Carrier Screening and Genomic Newborn Screening: Implications for Clinical Practice